Abstract
OBJECTIVE: A significant glob-al health issue that affects 25.5% of Saudi people is hypertension (HTN). According to internation-al recommendations, most HTN patients require more than one therapy to reach their blood pres-sure targets (BP). Therefore, it would be prefera-ble to utilize two medications from distinct classes separately or in a predetermined combination. Ac-cording to recent studies, a single-pill combination (SPC) may be more efficient. This study evaluated the safety and tolerability of Amlodipine/Valsartan (Aml/Val) SPC in Saudi hypertensive patients, as well as the effectiveness of the medication. PATIENTS AND METHODS: Observational re-search was done prospectively at the King Fahad Armed Forces Hospital in Jeddah, Saudi Arabia. The effectiveness of the treatment and the per-centage of 159 hypertensive patients who achieved the target blood pressure values (140/90; 130/80 mmHg) among those with diabetes mellitus (DM), chronic kidney disease (CKD), other cardiovascu-lar disorders, and responders were assessed from the beginning to the endpoint (week 23). RESULTS: According to the results, taking Aml/Val SPC significantly lowered all patients' baseline systolic and diastolic blood pressure readings by-17.97 and 8.58 mmHg, respectively. 43.4% of patients successfully met their BP ther-apeutic objectives by bringing their blood pres-sure levels back to normal, including 51.4% of patients under 65, 39.3% of patients with chron-ic kidney disease, and 26.2% of diabetic pa-tients. Aml/Val 10/160 mg significantly lowers SBP, more than Aml/Val 5/160 mg (-13.32% vs.-9.00%, p<0.050). Vertigo (6.30%), respiratory tract infections (4.0%), and ankle edema (2.50%) were the most frequent adverse events. CONCLUSIONS: Aml/Val SPC therapy effec-tively lowered BP and had few side effects while being well-tolerated in people with hypertension.